These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 34988829)

  • 1. ASO Author Reflections: Neoadjuvant Endocrine Therapy: A Pill in Time Saves Nine.
    Williams AD; Bleicher RJ
    Ann Surg Oncol; 2022 Mar; 29(3):1692-1693. PubMed ID: 34988829
    [No Abstract]   [Full Text] [Related]  

  • 2. ASO Author Reflections: Decisions, Decisions: Neoadjuvant Chemotherapy, Neoadjuvant Endocrine Therapy, or Primary Surgery?
    Cao L; Montero AJ; Shenk R; Miller ME
    Ann Surg Oncol; 2022 Dec; 29(Suppl 3):562-563. PubMed ID: 34405294
    [No Abstract]   [Full Text] [Related]  

  • 3. ASO Author Reflections: Nodal Downstaging and Conversion to Breast-Conserving Surgery Following Neoadjuvant Endocrine Therapy.
    Montagna G; Morrow M; Pilewskie M
    Ann Surg Oncol; 2020 Dec; 27(Suppl 3):693-694. PubMed ID: 32797378
    [No Abstract]   [Full Text] [Related]  

  • 4. ASO Author Reflections: Tailoring Axillary Surgery After Neoadjuvant Endocrine Therapy for Breast Cancer.
    Kantor O; King TA
    Ann Surg Oncol; 2021 Mar; 28(3):1368-1369. PubMed ID: 33389297
    [No Abstract]   [Full Text] [Related]  

  • 5. ASO Author Reflections: Objective Response Rate after Short Duration (< 9 Weeks) Is Not Inferior to Moderate (9-27 Weeks) or Long Duration (> 27 Weeks) of Neoadjuvant Endocrine Therapy (NET)-An NCDB Analysis.
    Burkbauer L; Goldbach MM; Tchou JC
    Ann Surg Oncol; 2021 Dec; 28(13):8663-8664. PubMed ID: 34304315
    [No Abstract]   [Full Text] [Related]  

  • 6. ASO Author Reflections: Mammographic Microcalcifications in Neoadjuvant Patients: Author Reflections.
    Azam R; Lim D; Curpen B; Mulligan AM; Hong NL
    Ann Surg Oncol; 2023 Jul; 30(7):4132-4133. PubMed ID: 37120486
    [No Abstract]   [Full Text] [Related]  

  • 7. ASO Author Reflections: Neoadjuvant Chemotherapy Switch: Optimizing Neoadjuvant Treatment Sequencing in Pancreas Cancer.
    Alva-Ruiz R; Truty MJ
    Ann Surg Oncol; 2022 Mar; 29(3):1592-1593. PubMed ID: 34705142
    [No Abstract]   [Full Text] [Related]  

  • 8. ASO Author Reflections: Assessing the Impact of Neoadjuvant Therapy: A Real View Perspective.
    Kamarajah SK; Phillips AW
    Ann Surg Oncol; 2020 Sep; 27(9):3193-3194. PubMed ID: 32227268
    [No Abstract]   [Full Text] [Related]  

  • 9. ASO Author Reflections: Biomarker Changes After Neoadjuvant Therapy: Do They Matter?
    Mohan SC; Chung A
    Ann Surg Oncol; 2021 Oct; 28(11):5918-5919. PubMed ID: 33791901
    [No Abstract]   [Full Text] [Related]  

  • 10. ASO Author Reflections: Multimodality Therapy for Patients with Pancreatic Cancer: Neoadjuvant Therapy for All?
    da Costa WL; Massarweh NN
    Ann Surg Oncol; 2021 Jun; 28(6):3196-3197. PubMed ID: 33221979
    [No Abstract]   [Full Text] [Related]  

  • 11. ASO Author Reflections: Immune Microenvironment Indicators in Neoadjuvant Chemo-Immunotherapy.
    Chen T; Cao Z; Sun Y; Huang J; Shen S; Jin Y; Jiang L; Wen F; Zhao X; Zhang D; Chen Y; Huang M; Chen H; Lu S; Li Z
    Ann Surg Oncol; 2023 Nov; 30(12):7590-7591. PubMed ID: 37598122
    [No Abstract]   [Full Text] [Related]  

  • 12. ASO Author Reflections: Impact of Neoadjuvant Chemotherapy on Exploration of Fertility Preservation.
    Crown A; Gemignani ML
    Ann Surg Oncol; 2020 Dec; 27(Suppl 3):699-700. PubMed ID: 32776189
    [No Abstract]   [Full Text] [Related]  

  • 13. ASO Author Reflections: Is Neoadjuvant Chemotherapy Associated with Acceptable Short-Term Outcomes for Pancreatic Cancer?
    Kamarajah SK; Dahdaleh F
    Ann Surg Oncol; 2021 Apr; 28(4):1906-1907. PubMed ID: 33389290
    [No Abstract]   [Full Text] [Related]  

  • 14. ASO Author Reflections: Impact of RAS Mutations on Total Neoadjuvant Therapy Outcomes in Rectal Cancer.
    Bedrikovetski S; Traeger L; Sammour T
    Ann Surg Oncol; 2024 Mar; 31(3):1692-1693. PubMed ID: 38127218
    [No Abstract]   [Full Text] [Related]  

  • 15. ASO Author Reflections: Future Prospects of Neoadjuvant Chemotherapy for Gastric Cancer.
    Kano M; Matsubara H
    Ann Surg Oncol; 2020 Dec; 27(Suppl 3):721-722. PubMed ID: 31797227
    [No Abstract]   [Full Text] [Related]  

  • 16. ASO Author Reflections: Neoadjuvant Treatment for Melanoma-Where Are We Now?
    Sharon CE; Karakousis GC
    Ann Surg Oncol; 2022 Dec; 29(13):8501-8502. PubMed ID: 35882694
    [No Abstract]   [Full Text] [Related]  

  • 17. ASO Author Reflections: Recurrence Following Post-neoadjuvant Pancreatectomy: How Can We Do Better?
    Maggino L; Malleo G; Crippa S; Falconi M; Salvia R
    Ann Surg Oncol; 2023 Jan; 30(1):220-221. PubMed ID: 36227393
    [No Abstract]   [Full Text] [Related]  

  • 18. ASO Author Reflections: The Pursuit of Eliminating Surgery after Neoadjuvant Systemic Therapy in Breast Cancer Patients.
    van Loevezijn AA; van Duijnhoven FH; Vrancken Peeters MTFD
    Ann Surg Oncol; 2021 Jun; 28(6):3254-3255. PubMed ID: 33301068
    [No Abstract]   [Full Text] [Related]  

  • 19. ASO Author Reflections: Changes in Use of Neoadjuvant Chemotherapy Over Time-Highest Rates of Use Now in Triple-Negative and HER2+ Disease.
    Murphy BL; Boughey JC
    Ann Surg Oncol; 2018 Dec; 25(Suppl 3):695-696. PubMed ID: 30465221
    [No Abstract]   [Full Text] [Related]  

  • 20. ASO Author Reflections: Rate of Axillary Lymph Node Dissection has Decreased in Patients Treated with Neoadjuvant Systemic Therapy.
    Nguyen TT; Boughey JC
    Ann Surg Oncol; 2018 Dec; 25(Suppl 3):693-694. PubMed ID: 30421050
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.